The Fifth IFSO Global Registry Report (2019) has been released at the XXIV World Congress of the International Federation for the Surgery of Obesity and Metabolic Disorders (IFSO) in Madrid, Spain. Published by Dendrite Clinical Systems, under the auspices of the IFSO, the publication reports data from more than 60 countries on over 833,000 operations including baseline obesity-related disease, operation types, operative outcomes and disease status after bariatric surgery.
Dendrite Clinical Systems has announced the installation of its National Bariatric Surgical Registry software at the Sheik Al Jaber Al Sabah Hospital, in Kuwait. The Sheik Al Jaber Al Sabah Hospital, opened by His Highness the Amir Sheikh Sabah Al-Ahmad Al- Jaber Al-Sabah in November 2018, consists of five towering 10-stories structures built on a 220,000 square meters and has a hospital bed capacity of around 1,160 with 36 operation rooms, a medical centre, a helipad and a parking lot accommodating some 5,000 vehicles.
Dendrite Clinical Systems and the Queen Mary Hospital in Hong Kong have launched the Asian Hypospadias Outcome Registry (AHOR), is a prospective web-based patient registry that will collect, record and analyse the treatment and outcomes of patients undergoing surgical repair.
Dendrite Clinical Systems has launched its ‘One-button push’ outcomes module, allowing clinicians to instantly produce their outcomes with the push of a single button. This enhancement is the latest in a series of advances incorporated into the company’s clinical registry software.
Dendrite Clinical Systems, the publisher of Bariatric News, is pleased to announce issue 40 of the newspaper is now available to view/download. The newspaper reports on research, technology, events and policy in the bariatric specialty, the latest clinical studies, policy changes and product news, the latest meetings and events, interviews prominent bariatric experts, and host debates between specialists on controversial topics.
Dendrite Clinical Systems – in collaboration with Haemotology Cancer Care (UCLH Charity), the Royal Free Charity, HaemSTAR (an organisation researching non-malignant haematology) and MPN Voice – have launched the MASCOT (Myeloproliferative Neoplasm Splanchnic Vein Thrombosis, MPN-SVT) Registry, a UK wide registry for patients with myeloproliferative diseases suffering from splanchnic or abdominal vein thrombosis.
An international team of scientists are investigating a possible curious bi-directional relationship between COVID-19 and diabetes. The researchers, who are part of the CoviDiab project, have hypothesised that the SARS-CoV-2 infection maybe be triggering the onset of diabetes, and they have established a global registry to track occurrence of events and are calling for doctors around the world to contribute reports of cases of new-onset diabetes associated with COVID-19.
The CoviDiab registry is utilising Dendrite Clinical Systems’ innovative “Intellect Web” software to collect new cases of diabetes in patients with COVID-19 to understand the extent and the characteristics of the manifestations of diabetes in patients with COVID-19, and the best strategies for the treatment and monitoring of affected patients, during and after the pandemic. Since the CoviDiab registry was launched a small but growing body of evidence suggests a relationship between new-onset diabetes and COVID-19.
“Over the last few months, we’ve seen more cases of patients that had either developed diabetes during the Covid-19 experience, or shortly after that,” Rubino recently told The Guardian. “We are now starting to think the link is probably true – there is an ability of the virus to cause a malfunctioning of sugar metabolism.”
Despite an association between newly diagnosed diabetes and COVID-19, questions remain regarding causation remain.
It is known SARS-Cov-2 binds to ACE-2 receptors, which are expressed in several key metabolic organs and tissues including the pancreatic β-cells, adipose tissue, small intestine, liver and kidney, CoviDiab researchers stated. Therefore, it is plausible that SARS-Cov-2 could cause multiple co-existing alterations of glucose metabolism that can complicate the pathophysiology of pre-existing diabetes or lead to new mechanisms of disease.
The goal of the registry is to establish the extent and phenotype of new-onset diabetes that is defined by hyperglycaemia, confirmed Covid-19, a negative history of diabetes, and a history of a normal glycated haemoglobin level. The registry, which will be expanded to include patients with pre-existing diabetes who present with severe acute metabolic disturbance, may also be used to investigate the epidemiologic features and pathogenesis of Covid-19–related diabetes and to gain clues regarding appropriate care for patients during and after the course of Covid-19.
The researchers indicated they plan to begin a preliminary analysis once the registry reaches 200 case reports.
To read additional news articles reporting on the CoviDiab project, please see:
For more information on the CoviDiab project, please click here
